In multivariate regression analysis, we assessed the impact of clinical and therapeutically parameters, such as menopausal status, age, grading, hormone receptor status, proliferation markers, chemotherapy, targeted therapy (also with anti-HER2 agents), and antihormonal therapy on the shift of HER2 expression from primary tumor to recurrent disease. The gene discussed is ERBB2; the disease is neoplasm.